Benitec Biopharma Inc (BNTC)

NASD · Healthcare · Biotechnology · USA

Benitec Biopharma Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines for rare diseases. Its lead program, BB-301, is an adeno-associated virus-based gene therapy using a "silence and replace" approach to treat Oculopharyngeal Muscular Dystrophy by permanently silencing disease-causing genes while restoring functional protein expression.

From its FY2026 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Benitec Biopharma Inc stock.

Our verdict on BNTC

Not valued: We cannot value this company yet.

ETFs with the most weight in BNTC

13 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than BNTC in Biotechnology

129 more in this industry show a wider margin of safety.

Is BNTC undervalued or overvalued?

We do not publish a verdict on BNTC yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of BNTC?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.